• Oropharyngeal cancer outcomes correlate with p16 status, multinucleation and immune infiltration.

  Wilde DC, Castro PD, Bera K, Lai S, Madabhushi A, Corredor G, Koyuncu C, Lewis JS, Lu C, Frederick MJ, Frederick AM, Haugen AE, Zevallos JP, Sturgis EM, Shi J, Huang AT, Hernandez DJ, Skinner HD, Kemnade JO, Yu W, Sikora AG, Sandulache VC.
  Mod Pathol. 2022 Aug. 8(35).

• Bite-size introduction to canine hematologic malignancies.

  Atherton MJ, Mason NJ.
  Blood Adv. 2022 Jul 12. 13(6).

• CD4+ T helper 2 cells suppress breast cancer by inducing terminal differentiation.

  Boieri M, Malishkevich A, Guennoun R, Marchese E, Kroon S, Trerice KE, Awad M, Park JH, Iyer S, Kreuzer J, Haas W, Rivera MN, Demehri S.
  J Exp Med. 2022 Jul 04. 7(219).

• Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment.

  Morimoto Y, Fushimi A, Yamashita N, Hagiwara M, Bhattacharya A, Cheng J, Frost TC, Ahmad R, Daimon T, Huang L, Hata T, Takahashi H, Yamamoto M, Suzuki Y, DeCaprio JA, Kufe D.
  Oncogene. 2022 Jul. 27(41).

• Potentiating adoptive cell therapy using synthetic IL-9 receptors.

  Kalbasi A, Siurala M, Su LL, Tariveranmoshabad M, Picton LK, Ravikumar P, Li P, Lin JX, Escuin-Ordinas H, Da T, Kremer SV, Sun AL, Castelli S, Agarwal S, Scholler J, Song D, Rommel PC, Radaelli E, Young RM, Leonard WJ, Ribas A, June CH, Garcia KC.
  Nature. 2022 Jul. 7918(607).

• MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma.

  Tao L, Mohammad MA, Milazzo G, Moreno-Smith M, Patel TD, Zorman B, Badachhape A, Hernandez BE, Wolf AB, Zeng Z, Foster JH, Aloisi S, Sumazin P, Zu Y, Hicks J, Ghaghada KB, Putluri N, Perini G, Coarfa C, Barbieri E.
  Nat Commun. 2022 Jun 28. 1(13).

• BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer.

  Rouanne M, Adam J, Radulescu C, Letourneur D, Bredel D, Mouraud S, Goubet AG, Leduc M, Chen N, Tan TZ, Signolle N, Bigorgne A, Dussiot M, Tselikas L, Susini S, Danlos FX, Schneider AK, Chabanon R, Vacher S, Bièche I, Lebret T, Allory Y, Soria JC, Arpaia N, Kroemer G, Kepp O, Thiery JP, Zitvogel L, Marabelle A.
  J Clin Invest. 2022 Jun 15. 12(132).

• Vaccines for immunoprevention of DNA mismatch repair deficient cancers.

  Hernandez-Sanchez A, Grossman M, Yeung K, Sei SS, Lipkin S, Kloor M.
  J Immunother Cancer. 2022 Jun. 6(10).

• The perception and response of T cells to a changing environment are based on the law of initial value.

  Huseby ES, Teixeiro E.
  Sci Signal. 2022 May 31. 736(15).

• CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies.

  Hwang JH, Arafeh R, Seo JH, Baca SC, Ludwig M, Arnoff TE, Sawyer L, Richter C, Tape S, Bergom HE, McSweeney S, Rennhack JP, Klingenberg SA, Cheung ATM, Kwon J, So J, Kregel S, Van Allen EM, Drake JM, Freedman ML, Hahn WC.
  Elife. 2022 May 12. (11).

• Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells.

  Anadon CM, Yu X, Hänggi K, Biswas S, Chaurio RA, Martin A, Payne KK, Mandal G, Innamarato P, Harro CM, Mine JA, Sprenger KB, Cortina C, Powers JJ, Costich TL, Perez BA, Gatenbee CD, Prabhakaran S, Marchion D, Heemskerk MHM, Curiel TJ, Anderson AR, Wenham RM, Rodriguez PC, Conejo-Garcia JR.
  Cancer Cell. 2022 May 09. 5(40).

• Preoperative immunotherapy for head and neck cancers: state of art.

  Egloff AM, Uppaluri R.
  Curr Opin Oncol. 2022 May 01. 3(34).

• Small molecule profiling to define synergistic EGFR inhibitor combinations in head and neck squamous cell carcinoma.

  Michmerhuizen NL, Ludwig ML, Birkeland AC, Nimmagadda S, Zhai J, Wang J, Jewell BM, Genouw D, Remer L, Kim D, Foltin SK, Bhangale A, Kulkarni A, Bradford CR, Swiecicki PL, Carey TE, Jiang H, Brenner JC.
  Head Neck. 2022 May. 5(44).

• Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma.

  Aiken TJ, Erbe AK, Zebertavage L, Komjathy D, Feils AS, Rodriguez M, Stuckwisch A, Gillies SD, Morris ZS, Birstler J, Rakhmilevich AL, Sondel PM.
  J Immunother Cancer. 2022 May. 5(10).

• Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer.

  Kuang Y, Ye N, Kyani A, Ljungman M, Paulsen M, Chen H, Zhou M, Wild C, Chen H, Zhou J, Neamati N.
  J Med Chem. 2022 Apr 28. 8(65).

• Genomic Hippo Pathway Alterations and Persistent YAP/TAZ Activation: New Hallmarks in Head and Neck Cancer.

  Faraji F, Ramirez SI, Anguiano Quiroz PY, Mendez-Molina AN, Gutkind JS.
  Cells. 2022 Apr 18. 8(11).

• CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity.

  Bernareggi D, Xie Q, Prager BC, Yun J, Cruz LS, Pham TV, Kim W, Lee X, Coffey M, Zalfa C, Azmoon P, Zhu H, Tamayo P, Rich JN, Kaufman DS.
  Nat Commun. 2022 Apr 07. 1(13).

• Global evolution of the tumor microenvironment associated with progression from preinvasive invasive to invasive human lung adenocarcinoma.

  Altorki NK, Borczuk AC, Harrison S, Groner LK, Bhinder B, Mittal V, Elemento O, McGraw TE.
  Cell Rep. 2022 Apr 05. 1(39).

• MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells.

  Bhattacharya A, Fushimi A, Yamashita N, Hagiwara M, Morimoto Y, Rajabi H, Long MD, Abdulla M, Ahmad R, Street K, Liu S, Liu T, Kufe D.
  Mol Cancer Res. 2022 Apr 01. 4(20).

• Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs.

  Gilardi M, Saddawi-Konefka R, Wu VH, Lopez-Ramirez MA, Wang Z, Soto F, Ramms DJ, Proietto M, Mikulski Z, Miki H, Sharabi A, Kupor D, Rueda R, Hollern DP, Wang J, Gutkind JS.
  Mol Cancer Ther. 2022 Apr 01. 4(21).

• PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.

  Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL, Plesa G, Vapiwala N, Chew A, Moniak M, Sebro RA, Farwell MD, Marshall A, Gilmore J, Lledo L, Dengel K, Church SE, Hether TD, Xu J, Gohil M, Buckingham TH, Yee SS, Gonzalez VE, Kulikovskaya I, Chen F, Tian L, Tien K, Gladney W, Nobles CL, Raymond HE, Hexner EO, Siegel DL, Bushman FD, June CH, Fraietta JA, Haas NB.
  Nat Med. 2022 Apr. 4(28).
  
  Clinical Trial

• Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses.

  Odunsi K, Qian F, Lugade AA, Yu H, Geller MA, Fling SP, Kaiser JC, Lacroix AM, D'Amico L, Ramchurren N, Morishima C, Disis ML, Dennis L, Danaher P, Warren S, Nguyen VA, Ravi S, Tsuji T, Rosario S, Zha W, Hutson A, Liu S, Lele S, Zsiros E, McGray AJR, Chiello J, Koya R, Chodon T, Morrison CD, Putluri V, Putluri N, Mager DE, Gunawan R, Cheever MA, Battaglia S, Matsuzaki J.
  Sci Transl Med. 2022 Mar 16. 636(14).
  
  Data

• Photon Counting CT and Radiomic Analysis Enables Differentiation of Tumors Based on Lymphocyte Burden.

  Allphin AJ, Mowery YM, Lafata KJ, Clark DP, Bassil AM, Castillo R, Odhiambo D, Holbrook MD, Ghaghada KB, Badea CT.
  Tomography. 2022 Mar 10. 2(8).

• Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity.

  Chakraborty S, Gonzalez JC, Sievers BL, Mallajosyula V, Chakraborty S, Dubey M, Ashraf U, Cheng BY, Kathale N, Tran KQT, Scallan C, Sinnott A, Cassidy A, Chen ST, Gelbart T, Gao F, Golan Y, Ji X, Kim-Schulze S, Prahl M, Gaw SL, Gnjatic S, Marron TU, Merad M, Arunachalam PS, Boyd SD, Davis MM, Holubar M, Khosla C, Maecker HT, Maldonado Y, Mellins ED, Nadeau KC, Pulendran B, Singh U, Subramanian A, Utz PJ, Sherwood R, Zhang S, Jagannathan P, Tan GS, Wang TT.
  Sci Transl Med. 2022 Mar 09. 635(14).

• Developmentally distinct CD4⁺ T_reg lineages shape the CD8⁺ T cell response to acute Listeria infection.

  Dolina JS, Lee J, Moore EL, Hope JL, Gracias DT, Matsutani T, Chawla A, Greenbaum JA, Linden J, Schoenberger SP.
  Proc Natl Acad Sci U S A. 2022 Mar 08. 10(119).

• Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.

  Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F, Ganguly S, Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi PN, Beitinjaneh A, Reagan PM, Herrera AF, Sauter CS, Kharfan-Dabaja MA, Hamadani M.
  Blood. 2022 Mar 03. 9(139).

• Immune Checkpoint Blockade and Skin Toxicity Pathogenesis.

  Ma B, Anandasabapathy N.
  J Invest Dermatol. 2022 Mar. 3 Pt B(142).

• Tumor-Infiltrating Lymphocytes in Patients With Advanced Laryngeal Cancer Undergoing Bioselection.

  Heft Neal ME, Smith JD, Birkeland AC, Haring CT, Chinn SB, Shuman AG, Casper KA, Malloy KM, Stucken CL, Mclean SA, Rosko AJ, Mierzwa ML, Shah J, Schonewolf C, Swiecicki PL, Worden FP, Wolf GT, Bradford CR, Prince MEP, Brenner JC, Spector ME.
  Otolaryngol Head Neck Surg. 2022 Mar. 3(166).

• Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer.

  McCann K, von Witzleben A, Thomas J, Wang C, Wood O, Singh D, Boukas K, Bendjama K, Silvestre N, Nielsen FC, Thomas G, Sanchez-Elsner T, Greenbaum J, Schoenberger S, Peters B, Vijayanand P, Savelyeva N, Ottensmeier C.
  J Immunother Cancer. 2022 Mar. 3(10).

• Practical and robust test for comparing binomial proportions in the randomized phase II setting.

  Attwood K, Park S, Hutson AD.
  Pharm Stat. 2022 Mar. 2(21).

• Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer.

  Xue D, Xu Y, Kyani A, Roy J, Dai L, Sun D, Neamati N.
  J Med Chem. 2022 Feb 24. 4(65).

• MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas.

  Luan Z, Morimoto Y, Fushimi A, Yamashita N, Suo W, Bhattacharya A, Hagiwara M, Jin C, Kufe D.
  Carcinogenesis. 2022 Feb 11. 1(43).

• IKKα-deficient lung adenocarcinomas generate an immunosuppressive microenvironment by overproducing Treg-inducing cytokines.

  Song NY, Li X, Ma B, Willette-Brown J, Zhu F, Jiang C, Su L, Shetty J, Zhao Y, Shi G, Banerjee S, Wu X, Tran B, Nussinov R, Karin M, Hu Y.
  Proc Natl Acad Sci U S A. 2022 Feb 08. 6(119).

• Activated B Cells and Plasma Cells Are Resistant to Radiation Therapy.

  Franiak-Pietryga I, Miyauchi S, Kim SS, Sanders PD, Sumner W, Zhang L, Mundt AJ, Califano JA, Sharabi AB.
  Int J Radiat Oncol Biol Phys. 2022 Feb 01. 2(112).

• Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer.

  Hampton JD, Peterson EJ, Katner SJ, Turner TH, Alzubi MA, Harrell JC, Dozmorov MG, Turner JBM, Gigliotti PJ, Kraskauskiene V, Shende M, Idowu MO, Puchalapalli M, Hu B, Litovchick L, Katsuta E, Takabe K, Farrell NP, Koblinski JE.
  Mol Cancer Ther. 2022 Feb. 2(21).

• Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis.

  Hamadani M, Gopal AK, Pasquini M, Kim S, Qiu X, Ahmed S, Lazaryan A, Bhatt VR, Daly A, Lulla P, Ciurea S, Gauthier J, Agrawal V, Grover NS, Lekakis L, Modi D, Dahi PB, Herr MM, Johnson PC, Hashmi H, Hematti P, Locke FL.
  Blood Adv. 2022 Jan 25. 2(6).

• Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors.

  Xue D, Xu Y, Kyani A, Roy J, Dai L, Sun D, Neamati N.
  J Med Chem. 2022 Jan 13. 1(65).

• TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures.

  Chaurio RA, Anadon CM, Lee Costich T, Payne KK, Biswas S, Harro CM, Moran C, Ortiz AC, Cortina C, Rigolizzo KE, Sprenger KB, Mine JA, Innamarato P, Mandal G, Powers JJ, Martin A, Wang Z, Mehta S, Perez BA, Li R, Robinson J, Kroeger JL, Curiel TJ, Yu X, Rodriguez PC, Conejo-Garcia JR.
  Immunity. 2022 Jan 11. 1(55).

• Regulation of antitumor immunity by inflammation-induced epigenetic alterations.

  Karin M, Shalapour S.
  Cell Mol Immunol. 2022 Jan. 1(19).

• Short-course neoadjuvant in situ vaccination for murine melanoma.

  Aiken TJ, Komjathy D, Rodriguez M, Stuckwisch A, Feils A, Subbotin V, Birstler J, Gillies SD, Rakhmilevich AL, Erbe AK, Sondel PM.
  J Immunother Cancer. 2022 Jan. 1(10).

• Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders.

  Zhou L, Zeng Z, Egloff AM, Zhang F, Guo F, Campbell KM, Du P, Fu J, Zolkind P, Ma X, Zhang Z, Zhang Y, Wang X, Gu S, Riley R, Nakahori Y, Keegan J, Haddad R, Schoenfeld JD, Griffith O, Manguso RT, Lederer JA, Liu XS, Uppaluri R.
  J Immunother Cancer. 2022 Jan. 1(10).

• Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling.

  Makino K, Long MD, Kajihara R, Matsueda S, Oba T, Kanehira K, Liu S, Ito F.
  J Immunother Cancer. 2022 Jan. 1(10).

• Case-cohort design in hematopoietic cell transplant studies.

  Cai J, Kim S.
  Bone Marrow Transplant. 2022 Jan. 1(57).

• Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma.

  Saglam O, Cao B, Wang X, Toruner GA, Conejo-Garcia JR.
  PLoS One. 2022. 2(17).

• Chronic activation of MUC1-C in wound repair promotes progression to cancer stem cells.

  Kufe DW.
  J Cancer Metastasis Treat. 2022. (8).

• Nanoprobes for Computed Tomography and Magnetic Resonance Imaging in Atherosclerosis Research.

  Ghaghada KB, Bhavane R, Badachhape A, Tanifum E, Annapragada A.
  Methods Mol Biol. 2022. (2419).

• Genetic Changes Driving Immunosuppressive Microenvironments in Oral Premalignancy.

  Rangel R, Pickering CR, Sikora AG, Spiotto MT.
  Front Immunol. 2022. (13).

• Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation.

  Mao Z, Nesterenko PA, McLaughlin J, Deng W, Burton Sojo G, Cheng D, Noguchi M, Chour W, DeLucia DC, Finton KA, Qin Y, Obusan MB, Tran W, Wang L, Bangayan NJ, Ta L, Chen CC, Seet CS, Crooks GM, Phillips JW, Heath JR, Strong RK, Lee JK, Wohlschlegel JA, Witte ON.
  Proc Natl Acad Sci U S A. 2022 Aug 02. 31(119).

• Comparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy.

  Chaudhry K, Dowlati E, Long MD, Geiger A, Lang H, Gomez EC, Muniraj N, Sanchez CE, Singh PK, Liu S, Bollard CM, Cruz CRY.
  Cytotherapy. 2022 Aug. 8(24).

• Sprod for de-noising spatially resolved transcriptomics data based on position and image information.

  Wang Y, Song B, Wang S, Chen M, Xie Y, Xiao G, Wang L, Wang T.
  Nat Methods. 2022 Aug. 8(19).

• Addiction of Cancer Stem Cells to MUC1-C in Triple-Negative Breast Cancer Progression.

  Yamashita N, Kufe D.
  Int J Mol Sci. 2022 Jul 26. 15(23).

• Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report.

  Gonugunta AS, von Itzstein MS, Gerber DE.
  J Med Case Rep. 2022 Jul 25. 1(16).

• Next-Generation CAR T-cell Therapies.

  Young RM, Engel NW, Uslu U, Wellhausen N, June CH.
  Cancer Discov. 2022 Jul 06. 7(12).

• Contribution of the Skin-Gut Axis to Immune-Related Adverse Events with Multi-System Involvement.

  Kuo AM, Kraehenbuehl L, King S, Leung DYM, Goleva E, Moy AP, Lacouture ME, Shah NJ, Faleck DM.
  Cancers (Basel). 2022 Jun 17. 12(14).

• Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes.

  Gillani R, Camp SY, Han S, Jones JK, Chu H, O'Brien S, Young EL, Hayes L, Mitchell G, Fowler T, Gusev A, Kamihara J, Janeway KA, Schiffman JD, Crompton BD, AlDubayan SH, Van Allen EM.
  Am J Hum Genet. 2022 Jun 02. 6(109).

• NF-κB: A Double-Edged Sword Controlling Inflammation.

  Liu D, Zhong Z, Karin M.
  Biomedicines. 2022 May 27. 6(10).

• DEPENDENCE ON THE MUC1-C ONCOPROTEIN IN CLASSIC, VARIANT AND NON-NEUROENDOCRINE SMALL CELL LUNG CANCER.

  Fushimi A, Morimoto Y, Ishikawa S, Yamashita N, Bhattacharya A, Daimon T, Rajabi H, Jin C, Hagiwara M, Yasumizu Y, Luan Z, Suo W, Wong KK, Withers H, Liu S, Long MD, Kufe D.
  Mol Cancer Res. 2022 May 25. ().

• Targeting MUC1-C Suppresses Chronic Activation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast Cancer.

  Yamashita N, Fushimi A, Morimoto Y, Bhattacharya A, Hagiwara M, Yamamoto M, Hata T, Shapiro GI, Long MD, Liu S, Kufe D.
  Cancers (Basel). 2022 May 24. 11(14).

• Validation of Monte Carlo ¹³¹ I radiopharmaceutical dosimetry workflow using a 3D-printed anthropomorphic head and neck phantom.

  Adam DP, Grudzinski JJ, Bormett I, Cox BL, Marsh IR, Bradshaw TJ, Harari PM, Bednarz BP.
  Med Phys. 2022 May 23. ().

• Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States.

  Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, Ahmed S, Ghobadi A, Miklos DB, Lin Y, Perales MA, Lunning MA, Herr MM, Hill BT, Ganguly S, Dong H, Nikiforow S, Hooper M, Kawashima J, Xu H, Pasquini MC.
  Transplant Cell Ther. 2022 May 21. ().

• Whole-Genome Sequencing Identifies PPARGC1A as a Putative Modifier of Cancer Risk in BRCA1/2 Mutation Carriers.

  Zhu Q, Wang J, Yu H, Hu Q, Bateman NW, Long M, Rosario S, Schultz E, Dalgard CL, Wilkerson MD, Sukumar G, Huang RY, Kaur J, Lele SB, Zsiros E, Villella J, Lugade A, Moysich K, Conrads TP, Maxwell GL, Odunsi K.
  Cancers (Basel). 2022 May 10. 10(14).

• Thymic Stromal Lymphopoietin Induction Suppresses Lung Cancer Development.

  Guennoun R, Hojanazarova J, Trerice KE, Azin M, McGoldrick MT, Schiferle EB, Stover MP, Demehri S.
  Cancers (Basel). 2022 Apr 27. 9(14).

• Tcf-1 protects anti-tumor TCR-engineered CD8⁺ T-cells from GzmB mediated self-destruction.

  Zangari B, Tsuji T, Matsuzaki J, Mohammadpour H, Eppolito C, Battaglia S, Ito F, Chodon T, Koya R, Robert McGray AJ, Odunsi K.
  Cancer Immunol Immunother. 2022 Apr 23. ().

• UACA locus is associated with breast cancer chemoresistance and survival.

  Zhu Q, Schultz E, Long J, Roh JM, Valice E, Laurent CA, Radimer KH, Yan L, Ergas IJ, Davis W, Ranatunga D, Gandhi S, Kwan ML, Bao PP, Zheng W, Shu XO, Ambrosone C, Yao S, Kushi LH.
  NPJ Breast Cancer. 2022 Mar 23. 1(8).

• A programmable encapsulation system improves delivery of therapeutic bacteria in mice.

  Harimoto T, Hahn J, Chen YY, Im J, Zhang J, Hou N, Li F, Coker C, Gray K, Harr N, Chowdhury S, Pu K, Nimura C, Arpaia N, Leong KW, Danino T.
  Nat Biotechnol. 2022 Mar 17. ().

• Cell-surface tethered promiscuous biotinylators enable comparative small-scale surface proteomic analysis of human extracellular vesicles and cells.

  Kirkemo LL, Elledge SK, Yang J, Byrnes JR, Glasgow JE, Blelloch R, Wells JA.
  Elife. 2022 Mar 08. (11).

• Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy.

  von Itzstein MS, Gonugunta AS, Sheffield T, Homsi J, Dowell JE, Koh AY, Raj P, Fattah F, Wang Y, Basava VS, Khan S, Park JY, Popat V, Saltarski JM, Gloria-McCutchen Y, Hsiehchen D, Ostmeyer J, Xie Y, Li QZ, Wakeland EK, Gerber DE.
  Cancers (Basel). 2022 Mar 04. 5(14).

• IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer.

  Mandal G, Biswas S, Anadon CM, Yu X, Gatenbee CD, Prabhakaran S, Payne KK, Chaurio RA, Martin A, Innamarato P, Moran C, Powers JJ, Harro CM, Mine JA, Sprenger KB, Rigolizzo KE, Wang X, Curiel TJ, Rodriguez PC, Anderson AR, Saglam O, Conejo-Garcia JR.
  Cancer Res. 2022 Mar 01. 5(82).

• Combined assessment of MHC binding and antigen abundance improves T cell epitope predictions.

  Koşaloğlu-Yalçın Z, Lee J, Greenbaum J, Schoenberger SP, Miller A, Kim YJ, Sette A, Nielsen M, Peters B.
  iScience. 2022 Feb 18. 2(25).

• The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma.

  Meier JA, Savoldo B, Grover NS.
  J Pers Med. 2022 Feb 01. 2(12).

• Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors.

  von Itzstein MS, Gonugunta AS, Wang Y, Sheffield T, Lu R, Ali S, Fattah FJ, Xie D, Cai J, Xie Y, Gerber DE.
  Cancer Immunol Immunother. 2022 Jan 24. ().

• Interleukin-12 as an in situ cancer vaccine component: a review.

  Cheng EM, Tsarovsky NW, Sondel PM, Rakhmilevich AL.
  Cancer Immunol Immunother. 2022 Jan 13. ().

• Shift of lung macrophage composition is associated with COVID-19 disease severity and recovery.

  Chen ST, Park MD, Del Valle DM, Buckup M, Tabachnikova A, Simons NW, Mouskas K, Lee B, Geanon D, D'Souza D, Dawson T, Marvin R, Nie K, Thompson RC, Zhao Z, LeBerichel J, Chang C, Jamal H, Chaddha U, Mathews K, Acquah S, Brown SA, Reiss M, Harkin T, Feldmann M, Powell CA, Hook JL, Kim-Schulze S, Rahman AH, Brown BD, Beckmann ND, Gnjatic S, Kenigsberg E, Charney AW, Merad M.
  bioRxiv. 2022 Jan 12. ().